BioCentury
ARTICLE | Financial News

Celgene's slide continues after refusal to file letter

February 28, 2018 9:34 PM UTC

Celgene Corp. (NASDAQ:CELG) shed $8.66 to $87.12 on Wednesday after FDA issued a refusal to file letter for an NDA for ozanimod (RPC1063) to treat multiple sclerosis. The news was announced after market close Tuesday (see BioCentury Extra, Feb. 27).

The company lost $6.5 billion in market cap on Wednesday and touched a 52-week low of $87.11 during intraday trading...